Manifestations of fulminant CD8 T-cell post-transplant lymphoproliferative disorder following the administration of rituximab for lymphadenopathy with a high level of Epstein-Barr Virus (EBV) replication after allogeneic hematopoietic stem cell transplantation.

MLA

Tanaka, Tomoyuki, et al. “Manifestations of Fulminant CD8 T-Cell Post-Transplant Lymphoproliferative Disorder Following the Administration of Rituximab for Lymphadenopathy with a High Level of Epstein-Barr Virus (EBV) Replication after Allogeneic Hematopoietic Stem Cell Transplantation.” Internal Medicine (Tokyo, Japan), vol. 53, no. 18, 2014, pp. 2115–19. EBSCOhost, https://doi.org/10.2169/internalmedicine.53.2384.

APA

Tanaka, T., Takizawa, J., Miyakoshi, S., Kozakai, T., Fuse, K., Shibasaki, Y., Moriyama, M., Ohshima, K., Toba, K., Furukawa, T., Sone, H., & Masuko, M. (2014). Manifestations of fulminant CD8 T-cell post-transplant lymphoproliferative disorder following the administration of rituximab for lymphadenopathy with a high level of Epstein-Barr Virus (EBV) replication after allogeneic hematopoietic stem cell transplantation. Internal Medicine (Tokyo, Japan), 53(18), 2115–2119. https://doi.org/10.2169/internalmedicine.53.2384

Chicago

Tanaka, Tomoyuki, Jun Takizawa, Shukuko Miyakoshi, Takashi Kozakai, Kyoko Fuse, Yasuhiko Shibasaki, Masato Moriyama, et al. 2014. “Manifestations of Fulminant CD8 T-Cell Post-Transplant Lymphoproliferative Disorder Following the Administration of Rituximab for Lymphadenopathy with a High Level of Epstein-Barr Virus (EBV) Replication after Allogeneic Hematopoietic Stem Cell Transplantation.” Internal Medicine (Tokyo, Japan) 53 (18): 2115–19. doi:10.2169/internalmedicine.53.2384.